Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RTA 402 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 25 mg | EXPERIMENTAL | 25 mg RTA 402 (Bardoxolone methyl)/Stratum 1 |
| 75 mg | EXPERIMENTAL | 75 mg RTA 402 (Bardoxolone methyl)/Stratum 1 |
| 150 mg | EXPERIMENTAL | 150 mg RTA 402 (Bardoxolone methyl)/Stratum 1 |
| 25/75 mg | EXPERIMENTAL | 25 mg -\> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2 |
| Name | Type | Description |
|---|---|---|
| RTA 402 (Bardoxolone Methyl) | DRUG | Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days |
Inclusion Criteria: 1. Diagnosis of type 2 diabetes; 2. Serum creatinine in women 1.3 - 3.0 mg/dL (115-265 μmol/L), inclusive, and in men 1.5 - 3.0 mg/dL (133-265 μmol/L), inclusive; 3. Patient must agree to practice effective contraception. 4. Patient must have a negative urine pregnancy test with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Renal Autologous Cell Therapy |
RTA 402 is an investigational small molecule being studied for the treatment of diabetic nephropathy, a kidney condition that can occur in people with diabetes. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
RTA 402 is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with diabetic nephropathy.
RTA 402 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied for its effects on renal function in patients with diabetic nephropathy.
RTA 402 has one completed clinical trial, identified as NCT00664027. This was a Phase IIa trial that enrolled 80 participants in the United States to determine the effects of bardoxolone methyl on renal function in patients with diabetic nephropathy. The trial was controlled but not double-blinded.
Yes, RTA 402 is also known as bardoxolone methyl. The clinical trial NCT00664027, which studied RTA 402, is titled 'Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy.'